Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

2.3%

1 terminated/withdrawn out of 44 trials

Success Rate

95.7%

+9.2% vs industry average

Late-Stage Pipeline

5%

2 trials in Phase 3/4

Results Transparency

0%

0 of 22 completed trials have results

Key Signals

19 recruiting

Enrollment Performance

Analytics

Phase 1
20(45.5%)
Phase 2
17(38.6%)
Early Phase 1
5(11.4%)
Phase 3
1(2.3%)
Phase 4
1(2.3%)
44Total
Phase 1(20)
Phase 2(17)
Early Phase 1(5)
Phase 3(1)
+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (44)

Showing 20 of 44 trials
NCT05145361Early Phase 1Recruiting

Clinical Study of B001 Injection in Subjects With Neuromyelitis Optic Spectrum Disorder (NMOSD)

Role: lead

NCT06413654Phase 2Recruiting

A Clinical Study of B001 Injection in the Treatment of Neuromyelitis Optica Spectrum Disorders(NMOSD)

Role: collaborator

NCT05245058Early Phase 1Recruiting

SPH5030 Tablets in Subjects With Advanced Her2-positive Solid Tumors

Role: lead

NCT05872347Phase 2Recruiting

Efficacy and Safety of SPH4336 in Combination With Endocrine Therapy in Breast Cancer Patients With Brain Metastases.

Role: lead

NCT06483373Early Phase 1Recruiting

A Clinical Study of SPH7854 Granules in Healthy Subjects.

Role: lead

NCT06470191Phase 2Recruiting

A Clinical Study of B007 in the Treatment of Primary Membranous Nephropathy.

Role: collaborator

NCT06434610Phase 2Recruiting

A Study of B013 in Combination With Paclitaxel in Patients With Platinum-resistant Recurrent Ovarian Cancer.

Role: collaborator

NCT06839131Phase 1Recruiting

A Clinical Study of SPH9788 Tablets in Healthy Chinese Subjects.

Role: lead

NCT06214143Phase 1Recruiting

A Clinical Study of T3011 in Combination With PD-1/PD-L1 Inhibitors in Subjects With Advanced Solid Tumors

Role: lead

NCT06454357Phase 2Recruiting

A Clinical Study of B007 in the Treatment of Pemphigus.

Role: collaborator

NCT05686642Phase 2Recruiting

Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke

Role: lead

NCT05668403Phase 1Recruiting

A Phase I Clinical Study of Recombinant Humanized Anti-CD20(B-lymphocyte Antigen CD20) Monoclonal Antibody Subcutaneous Injection in the Treatment of Primary Membranous Nephropathy

Role: collaborator

NCT06447597Phase 2Recruiting

A Clinical Study of B007 in the Treatment of Generalized Myasthenia Gravis.

Role: collaborator

NCT05046314Phase 2Completed

A Clinical Study of TK216 in Patients With Relapsed or Refractory Ewing's Sarcoma

Role: lead

NCT06214156Phase 1Recruiting

A Clinical Study of T3011 in Subjects With Advanced Melanoma

Role: lead

NCT05860465Phase 2Recruiting

Safety and Efficacy of SPH4336 in Combination With Endocrine Therapy in the Treatment of Locally Advanced or Metastatic Breast Cancer

Role: lead

NCT05944224Phase 1Recruiting

A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.

Role: lead

NCT05770609Phase 2Completed

A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative Colitis

Role: lead

NCT06487455Phase 1Recruiting

A Clinical Study of SPH7485 Tablets in the Treatment of Advanced Solid Tumors.

Role: lead

NCT05744687Phase 2Recruiting

Phase II/III Study of SPH4336 Combined With Letrozole vs Placebo Combined With Letrozole in First-line Treatment of Breast Cancer

Role: lead